Zacks Research Decreases Earnings Estimates for Cytosorbents

Cytosorbents Corporation (NASDAQ:CTSO) – Zacks Research cut their FY2026 earnings per share (EPS) estimates for Cytosorbents in a report issued on Thursday, May 21st. Zacks Research analyst T. Kerr now expects that the medical research company will post earnings per share of ($0.20) for the year, down from their prior estimate of ($0.19). The consensus estimate for Cytosorbents’ current full-year earnings is ($0.18) per share.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings data on Wednesday, May 13th. The medical research company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Cytosorbents had a negative return on equity of 235.57% and a negative net margin of 31.85%.The company had revenue of $8.86 million for the quarter, compared to analysts’ expectations of $9.40 million.

Other equities analysts also recently issued research reports about the company. D. Boral Capital reiterated a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a research report on Thursday, March 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cytosorbents in a research report on Wednesday, April 8th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $5.38.

Cytosorbents Stock Performance

Shares of Cytosorbents stock opened at $0.46 on Wednesday. Cytosorbents has a one year low of $0.44 and a one year high of $1.39. The company has a market cap of $29.05 million, a price-to-earnings ratio of -2.43 and a beta of 1.43. The company has a debt-to-equity ratio of 4.70, a quick ratio of 0.81 and a current ratio of 1.09. The business’s 50 day moving average price is $0.59 and its 200 day moving average price is $0.66.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CTSO. CM Management LLC grew its stake in Cytosorbents by 14.6% during the 4th quarter. CM Management LLC now owns 1,476,500 shares of the medical research company’s stock worth $944,000 after purchasing an additional 188,372 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new position in shares of Cytosorbents during the 3rd quarter worth about $161,000. Avenir Corp boosted its position in shares of Cytosorbents by 2.9% during the 4th quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock worth $3,343,000 after acquiring an additional 147,261 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of Cytosorbents during the 3rd quarter worth about $105,000. Finally, Vanguard Group Inc. boosted its position in shares of Cytosorbents by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock worth $2,059,000 after acquiring an additional 79,535 shares in the last quarter. 32.87% of the stock is owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.